Komori
Changes in Officers4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding a Change in Representative Director (Change of President)

The Representative Director and President will change from 五十嵐新 (Igarashi Arata) to 平井友行 (Hirai Tomoyuki), and 五十嵐新 (Igarashi Arata) will become Chairman of the Board. 平井友行 (Hirai Tomoyuki) will be promoted from Senior Managing Director to Representative Director and President.

Worth reading
49Recurring
Scored from 4 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Who is moving to which position

Resolved 26 February 2026

Incoming appointee

1 item
Scheduled Appointment Date1 April 2026
Hirai Tomoyuki (平井 友行)
Previous positionManaging Director
New positionRepresentative Director and President
生年月日 1965年10月9日入社年 2023所有株式数 5,000株(2025年9月30日現在)

Departing officer

1 item
Igarashi Arata (五十嵐 新)Next role stated
Former PositionRepresentative Director and President
New positionChairman of the Board

“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.

Whether the incumbent will remain in office (whether they will retain their position)

Will remain on the Board of Directors as Chairman of the Board

Reason for change

2028年度をゴールとする中期経営計画が開始から2年が経過し、概ね計画通りに進捗するなか、今後の持続的な成長と一層の企業価値の向上を実現するため、代表取締役の異動を行うことを決定いたしました。

Who is moving to which position
ItemDetails
Resolution date26 February 2026
Scheduled Appointment Date1 April 2026
Name of appointeeHirai Tomoyuki (平井 友行)
Appointee's new positionRepresentative Director and President
Appointee's previous positionManaging Director
Appointee's date of birth1965年10月9日
Year the appointee joined the Company2023
Number of shares held by the appointee5,000株(2025年9月30日現在)
Name of departing officerIgarashi Arata (五十嵐 新)
Former position of departing officerRepresentative Director and President
New position of departing officerChairman of the Board
Whether the incumbent will remain in officeWill remain on the Board of Directors as Chairman of the Board
Reason for change2028年度をゴールとする中期経営計画が開始から2年が経過し、概ね計画通りに進捗するなか、今後の持続的な成長と一層の企業価値の向上を実現するため、代表取締役の異動を行うことを決定いたしました。
Items this document does not state (8)
Date of departureReason for departureReasons for appointmentNumber of directors after the changeFiling as an independent officerDetails of organizational changesChange in Corporate Governance StructureSubject to Approval by the General Meeting of Shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

2028年度をゴールとする中期経営計画が開始から2年経過し、概ね計画通りに進捗するなか、今後の持続的な成長と一層の企業価値の向上を実現するため。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding a Change in Representative Director (Change of President) | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori